Hong Kong: South Korean drugmaker Celltrion Inc. plans to achieve annual sales of 5 trillion won (US$3.58 billion) next year, driven by the growth of its biosimilar products and a new treatment for autoimmune diseases, its chairman said Wednesday.According to Yonhap News Agency, the 2025 sales target is 50 percent higher than the 3.5 trillion won of annual revenue expected to be recorded this year, Celltrion Chairman Seo Jung-jin revealed during an investors relations meeting in Hong Kong livestreamed via YouTube in South Korea. Seo expressed confidence that by 2027, the company will also be able to post an annual revenue of 10 trillion won.Seo outlined plans for Celltrion to introduce 11 products to the global market by 2025, including Zymfentra, which reached the U.S. market earlier this year. These products are expected to drive Celltrion's revenue growth. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab Remsima, an autoimmune disease treatment. Looking further ahead, Celltri on plans to commercialize 22 products, including biosimilars, by 2030.In addition to product expansion, Seo announced the company's strategy to venture into the contract research, development, and manufacturing organization (CRDMO) business. As initially mentioned during the Morgan Stanley Global Healthcare Conference in September, Celltrion will establish a CRDMO subsidiary in South Korea by the end of this year, along with constructing a production facility with a capacity of 200,000 liters in the country."We expect to make a profit from the CRDMO business starting in 2028. To foster this business, we will establish research centers in the U.S., Europe, and India," Seo stated, highlighting the company's global ambitions and commitment to growth.
- October 12, 2026
